Attitudinal barriers to delivery of race-targeted pharmacogenomics among informed lay persons
Attitudinal barriers to delivery of race-targeted pharmacogenomics among informed lay persons
复制标题
DOI：
10.1097/01.gim.0000087990.30961.72
复制
发表时间：
2003-09-01
影响因子：
8.8
通讯作者：
Harris, TM
中科院分区：
文献类型：
--
作者：
Condit, C;Templeton, A;Harris, TM
目的：确定潜在患者对基于种族的药物基因组学研究的态度。方法：对2002年2~4月和2002年8~11月对城市、郊区和农村社区的少数民族人群进行了两套超额抽样的无记名问卷调查和定性问卷调查。结果：参与者并不完全将“种族”与大陆集群联系在一起。他们对最近的祖先了解不完全(39.6%的人不认识他们所有的亲生祖父母)。他们对带有种族标签的药物高度怀疑；47.5%的人表示他们会非常怀疑其安全性，40.6%的人表示他们会非常怀疑其疗效。相当大一部分非裔美国人参与者(13.2%)更愿意服用专为欧洲裔美国人设计的药物。讨论基于种族的医学对种族态度的影响是模棱两可的。结论：患者对血统的了解和对种族药物的怀疑构成了在判断基于种族的药物基因组学可能的有效性时需要纳入的实质性障碍。
Objectives: To ascertain attitudes of prospective patients relevant to the delivery of race-based pharmacogenomics. Methods: Written anonymous survey and qualitative responses in two sets of reactance format focus groups over-sampled for minority groups in urban, suburban, and rural communities conducted from February through April, 2002 [N = 104] and August through November, 2002 [N = 120]. Results: Participants do not associate "races" exclusively with continental clusters. They have incomplete knowledge of their recent ancestors (39.6% do not know all their biological grandparents). They would be highly suspicious of race-labeled drugs; with 47.5% saying they would be very suspicious of their safety and 40.6% indicating they would be very suspicious of their efficacy. A substantial minority of African-American participants (13.2%) would prefer to take the drugs designated for European Americans. Effect of discussion of race-based medicine on racial attitudes is ambiguous. Conclusions: Patient knowledge of ancestry and suspicion of race-designated drugs constitute substantial barriers that need to be incorporated in judging the likely effectiveness of race-based pharmacogenomics.